|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
245 Main St, Cambridge, MA 02142, US
|
|
FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC). Our goal is to provide greater hope to patients with this disease, who have seen little improvement in their standard of care over the past 20 years.
FerGene, Inc. is a privately held company, created through a joint partnership between Ferring Pharmaceuticals and Blackstone Life Sciences. With over $570 million in funding, FerGene is preparing to commercialize nadofaragene firadenovec (rAd-IFN/Syn3) for high-grade, BCG-unresponsive NMIBC for the US market. Phase 3 data for nadofaragene firadenovec were presented at the Society of Urologic Oncology Congress in December 2019.
|
FerGene Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
100%
|
The widely used FerGene email format is {first}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact FerGene customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.